205 results on '"Halaban, Ruth"'
Search Results
2. Clonal determinants of organotropism and survival in metastatic uveal melanoma
3. Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma
4. Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction
5. Interferon-stimulated neutrophils as a predictor of immunotherapy response
6. Unannotated microprotein EMBOW regulates the interactome and chromatin and mitotic functions of WDR5
7. CD4 T cells and toxicity from immune checkpoint blockade
8. Abstract 6670: Association between circulating CD4 memory T cell levels and severe immune-related adverse events in melanoma patients treated with immune checkpoint blockade
9. Supplementary Figure 6 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
10. Supplementary Figure 4 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
11. Supplementary Tables 1-3 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
12. Supplementary Figure 3 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
13. Supplementary Figure 1 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
14. Supplementary Figure 2 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
15. Supplementary Tables 1-3 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
16. Supplementary Figure 1 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
17. Supplementary Figure 2 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
18. Supplementary Table 4 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
19. Data from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
20. Data from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
21. Supplementary Table 4 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
22. Supplementary Table 5 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
23. Supplementary Figure 1 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
24. Data from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
25. Supplemental Material, Supplementary Figures 1 and 2, Supplemental Tables 1 - 8 from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
26. Supplementary Figure 6 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
27. Supplementary Figure 1 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
28. Supplementary Table 5 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
29. Data from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
30. Supplementary Figure 5 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
31. Data from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
32. Supplementary Table 6 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
33. Data from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
34. Supplementary Figure 5 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
35. Supplementary Figure 3 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
36. Supplementary Figure 7 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
37. Supplementary Figure 7 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
38. Supplementary Figure 4 from Preexisting MEK1 Exon 3 Mutations in V600E/KBRAF Melanomas Do Not Confer Resistance to BRAF Inhibitors
39. Supplemental Material, Supplementary Figures 1 and 2, Supplemental Tables 1 - 8 from A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma
40. Supplementary Table Legends 1-6, Figure Legend 1 from Phosphoproteomic Screen Identifies Potential Therapeutic Targets in Melanoma
41. Supplementary Figure S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
42. Supplementary Figure Legends from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
43. Supplementary Table S3 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
44. Supplementary Figure S1 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
45. Supplementary Table S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
46. Supplementary Figure S4 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
47. Supplementary Table S2 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
48. Supplementary Figure S3 from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
49. Supplementary Figures S1-S5 from Plasma Markers for Identifying Patients with Metastatic Melanoma
50. Supplementary Materials and Methods from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.